Compare SMTI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMTI | SERA |
|---|---|---|
| Founded | 1982 | 2008 |
| Country | United States | United States |
| Employees | 108 | N/A |
| Industry | Medical/Dental Instruments | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.8M | 75.2M |
| IPO Year | 2008 | 2021 |
| Metric | SMTI | SERA |
|---|---|---|
| Price | $22.98 | $2.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $34.00 | N/A |
| AVG Volume (30 Days) | 39.1K | ★ 57.8K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $15,586,976.00 | $81,000.00 |
| Revenue This Year | $17.31 | $554.81 |
| Revenue Next Year | $12.48 | $517.27 |
| P/E Ratio | $476.20 | ★ N/A |
| Revenue Growth | ★ 32.47 | 5.19 |
| 52 Week Low | $16.05 | $1.37 |
| 52 Week High | $35.70 | $4.09 |
| Indicator | SMTI | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 61.81 | 59.00 |
| Support Level | $22.60 | $1.73 |
| Resistance Level | $24.33 | $2.41 |
| Average True Range (ATR) | 1.42 | 0.24 |
| MACD | 0.18 | 0.06 |
| Stochastic Oscillator | 79.27 | 70.38 |
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.